Neuronal Exosomes Reveal Alzheimer'S Disease Biomarkers In Down Syndrome
Introduction Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid Î² (AÎ²) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD. Methods AD neuropathogenic proteins AÎ²1â€“42, P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls. Results Neuronal exosome levels of AÎ²1â€“42, P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with age-matched controls at all ages beginning in childhood. No significant gender differences were observed. Discussion These early increases in AÎ²1â€“42, P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available.
Alzheimer's and Dementia
Digital Object Identifier (DOI)
Hamlett, Eric D.; Goetzl, Edward J.; Ledreux, AurÃ©lie; Vasilevko, Vitaly; Boger, Heather A.; LaRosa, Angela; Clark, David; Carroll, Steven L.; Carmona-Iragui, MarÃa; Fortea, Juan; Mufson, Elliott J.; Sabbagh, Marwan; Mohammed, Abdul H.; Hartley, Dean; Doran, Eric; Lott, Ira T.; and Granholm, Ann Charlotte, "Neuronal Exosomes Reveal Alzheimer'S Disease Biomarkers In Down Syndrome" (2017). Translational Neuroscience. 337.